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Lenalidomide is a 2
nd generation immunomodulatory
drug (IMiD) that has shown remarkable activity in the
treatment of multiple myeloma (MM). In comparison
with its parent drug thalidomide, lenalidomide has the
advantage of having no neurological toxicity.  
Two phase III randomized studies validated the role of
lenalidomide in combination with dexamethasone (RD) for
the treatment of relapsed/refractory MM patients. In both
studies, RD induced higher responses compared with dex-
amethasone alone with a clear advantage in terms of time-
to-progression.1,2 These results led the US Food and Drug
Administration to grant approval to lenalidomide in combi-
nation with dexamethasone in patients with MM who
have received one prior therapy.
Various trials have tested lenalidomide plus dexametha-
sone for the treatment of newly diagnosed MM patients,
confirming its efficacy.3 Recently, the MM-015 trial com-
pared melphalan-prednisone-lenalidomide followed by
lenalidomide maintenance (MPR-R) with melphalan-pred-
nisone-lenalidomide (MPR) and melphalan-prednisone
(MP) in newly diagnosed elderly MM.4 The complete
response (CR) rate was superior with MPR-R compared to
both MPR and MP. MPR-R also significantly prolonged
median progression-free survival (PFS), with the greatest
advantage in patients aged 65-75 years of age. A landmark
analysis from start of maintenance showed that lenalido-
mide maintenance significantly prolonged PFS as compared
to placebo, regardless of age. The immunomodulatory
activity of lenalidomide prompted its use in MM patients
receiving allogeneic stem cell transplantation (allo-SCT).
Only few efficacy and safety data on lenalidomide are avail-
able for relapsed/refractory patients receiving immunosup-
pressive drugs after allo-SCT. Small studies showed a high
efficacy of lenalidomide in this setting.5,6 Yet, there are some
concerns about the risk of acute graft-versus-host disease
(GVHD) under this treatment, particularly when lenalido-
mide is given as maintenance therapy after allo-SCT.7
The positive results achieved in MM patients provided
the rationale to investigate the role of lenalidomide for the
treatment of AL amyloidosis. AL amyloidosis patients have
multi-organ dysfunction, which makes them more suscep-
tible to treatment toxicity, and thus have a poor prognosis.
Lenalidomide was shown to be beneficial in patients previ-
ously treated with chemotherapy/bortezomib and in those
refractory to thalidomide. However, this improvement was
accompanied by a significant increase in toxicity, especially
in patients with a heart condition. In various small trials,
lenalidomide combined with alkylator agents induced an
up to 77% hematologic response, although a substantial
proportion of patients experienced grade 3-4 toxicities.8-11
In the current issue of the Journal, three interesting papers
have been published evaluating the role of lenalidomide
alone or in combination with steroids and alkylating agents
in three different settings of patients with plasma cell
dyscrasia.12-14
Coman et al. presented the results of a retrospective mul-
ticenter study on MM patients receiving lenalidomide alone
or in combination with dexamethasone as salvage therapy
after allo-SCT.12 This study is the largest reported in this set-
ting. Overall response rate was 83%, including 29% of CR.
This is quite an impressive result, as all patients enrolled in
the study received a median of two treatment lines before
allo-SCT, and the majority of them had already been
exposed to at least one IMiD or achieved less than a partial
response (PR) to IMiDs. These data confirm those reported
in previous smaller series and suggest that lenalidomide has
higher efficacy compared with thalidomide, comparable to
that of bortezomib.12 The toxicity profile of the treatment
was in line with that reported in previous studies and led to
dose reductions and treatment interruption in 44% and
17% of patients, respectively.
De novo or exacerbation of pre-existing acute GVHD
occurred in one-third of patients and was correlated with
the early introduction of lenalidomide after allo-SCT. All
cases of GVHD could be controlled, although one patient
died from sepsis. The issue of acute GVHD has been raised
also by other groups, and in the maintenance setting the
risk of acute GVHD overweighed the benefit associated
with treatment.7 However, the occurrence of acute GVHD
on treatment was the only factor significantly associated
with an improved anti-myeloma response in this trial. This
could be due to the potential of lenalidomide to enhance
the immunologic graft-versus-myeloma effect. Despite a
beneficial impact of the occurrence of acute GVHD on the
overall response rate, no benefit in terms of PFS or OS was
noted. The authors suggest that the shorter duration of
lenalidomide therapy in case of GVHD occurrence could
explain in part the absence of improved PFS. Interestingly,
only 26% of the patients who had maintained lenalidomide
after achieving the best response relapsed, as compared
with 56% of those who stopped immediately after achiev-
ing the best response. Overall, the results presented by
Coman et al. are promising and support the use of lenalido-
mide in a salvage setting after allo-SCT. However, larger
studies are needed to assess the best timing and dosage, and
the most appropriate duration of lenalidomide treatment
after allo-SCT. 
Dimopoulos M et al. assessed the impact of lenalidomide-
based therapy on health-related Quality of Life (HRQoL) in
459 patients enrolled in the MM-015 trial.13 The main
results of the MM-015 trial have been recently published
(see above4). With the increasing availability of effective
treatments, the main goal of myeloma therapy should be to
improve survival while maintaining a good Quality of Life.
Clinical trials are increasingly evaluating HRQoL. In the
MM-015 trial, patients were asked to complete HRQoL
questionnaires at baseline, after every third treatment cycle,
and on completion of treatment. HRQoL improved in all
treatment groups during induction therapy. The improve-
ment from baseline was slightly greater in MPR-R patients
aged 65-75 years, and the most pronounced improvement
was observed in patients receiving lenalidomide mainte-
nance. Overall, changes in HRQoL score from baseline
were generally higher in patients who received lenalido-
mide. These results demonstrate that MPR-R was not only
effective and safe in newly diagnosed elderly MM patients,
but it was also associated with improved HRQoL. An
increasing number of clinical trials are now including main-
tenance therapy, and survival benefits were reported in
both patients eligible and ineligible for transplantation.
Because continuous therapy aims to control disease, long-
term tolerability of this strategy is crucial. Different trials
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assessed thalidomide maintenance, and this approach was
not always well tolerated.15-18 Stewart et al. have recently
reported that maintenance therapy with thalidomide-pred-
nisone after autologous stem cell transplantation (ASCT)
improved the duration of disease control but was associated
with worsening of patient-reported HRQoL, without a
detectable OS benefit.18 These findings further support the
concept that the choice of the most appropriate mainte-
nance treatment should carefully balance the potential ben-
efits and risks associated with this strategy, as none of the
novel agents is currently approved for maintenance therapy.
In another study presented in this issue of the Journal,
Sanchorawala et al. reported the results of a phase II trial of
melphalan-lenalidomide-dexamethasone (MLd) for the
treatment of AL amyloidosis.14 Various phase II studies
showed the efficacy of lenalidomide plus dexamethasone in
AL amyloidosis,8,9 and subsequent studies tested lenalido-
mide combination with alkylating agents.10,11,19 The tolera-
bility of such combinations was not always acceptable. In
the study conducted by Sanchorawala et al., the median age
was 70 years. The majority of patients experienced grade 3-
4 adverse events, with myelosuppression being the most
common toxicity and 85% of patients requiring dose reduc-
tions. This high rate of toxicity was not compensated by a
significant efficacy advantage. The PR rate was disappoint-
ing (43% with 7% CR). Due to these negative results, the
trial was stopped. Side effects reported in this trial were
greater than those seen in a previous study,19 and this may
be attributed to the higher median age of the study popula-
tion (70 years compared with 57 years in the French study).
This combination required dose reductions to prevent grade
3-4 toxicities and induced response rates that were no bet-
ter than those seen with either melphalan or lenalidomide
alone. The combination of lenalidomide-dexamethasone
plus cyclophosphamide was better tolerated, although tox-
icity was not negligible.10,11 Based on the current data, the
combination of lenalidomide and alkylating agents should
not be suggested, in particular in elderly and unfit patients.
Available data indicate that in AL amyloidosis, as well as in
MM, prolonged exposure to lenalidomide may improve
patient outcome.20 Trials to assess the value of maintenance
therapy in this disease are warranted. 
Lenalidomide is currently approved for the treatment of
relapsed/refractory MM, and data presented in the allo-
geneic setting strengthen its role also in heavily pre-treated
patients. However, results of first-line therapy suggest that
lenalidomide is a valuable option, particularly as mainte-
nance therapy, with the greatest benefit in young fit
patients, while gentler approaches with correct and appro-
priate dose reductions are needed for the frail/unfit popula-
tion. The efficacy of a treatment should always be balanced
against its safety profile, and an effective treatment should
be well tolerated and associated with improved Quality of
Life. 
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